Co-Authors
This is a "connection" page, showing publications co-authored by SUSAN LYNNE MCGOVERN and WAFIK ZAKY.
Connection Strength
0.867
-
Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023 Jul; 163(3):717-726.
Score: 0.227
-
Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac129.
Score: 0.214
-
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma. Neuro Oncol. 2024 May 03; 26(Supplement_2):S155-S164.
Score: 0.060
-
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
Score: 0.056
-
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac143.
Score: 0.054
-
Contrast Enhancement Patterns in Pediatric Glioblastomas. J Comput Assist Tomogr. 2023 Jan-Feb 01; 47(1):115-120.
Score: 0.054
-
Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors. Neuro Oncol. 2022 09 01; 24(9):1571-1581.
Score: 0.054
-
Reevaluating surgery and re-irradiation for locally recurrent pediatric ependymoma-a multi-institutional study. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab158.
Score: 0.051
-
Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079.
Score: 0.049
-
Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2021 07 01; 127(13):2368-2375.
Score: 0.048